

References

1. Sun T. 2011. Clinical Application, Case 16, Ch 6. In *Flow Cytometry and Immunohistochemistry for Hematologic Neoplasms*, 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins.

Chronic Lymphocytic Leukemia (CLL)



testing at ARUP Laboratories



www.aruplab.com

ARUP LABORATORIES
500 Chipeta Way
Salt Lake City, UT 84108-1221
Phone: (800) 522-2787
Fax: (801) 583-2712

keyword: CLL


A nonprofit enterprise of the University of Utah and its Department of Pathology

© 2018 ARUP Laboratories
BD-CS-039, Rev 2, May 2018



[www.aruplab.com/
topics/CLL](http://www.aruplab.com/topics/CLL)

Chronic lymphocytic leukemia (CLL) is characterized by small lymphocytes in the bone marrow, blood, and lymphoid tissues. CLL is the most common form of leukemia in adults in the U.S. and represents **40% of all adult leukemias in Western countries.**¹



Cytogenetic, molecular, and flow cytometric testing play an important role in prognostication for CLL patients.

ARUP TEST CODE AND NAME		RECOMMENDED USE
2002290	Chromosome Analysis, Leukemic Blood	For diagnosis, prognosis, and monitoring of hematopoietic neoplasms.
2002292	Chromosome Analysis, Bone Marrow	For diagnosis, prognosis, and monitoring of hematopoietic neoplasms.
2002295	Chromosome FISH, CLL Panel	Alternate test to detect prognostically important genomic abnormalities in CLL.
2006325	Cytogenomic SNP Microarray—Oncology	Monitors disease progression and response to therapy. Preferred test on fresh specimens at time of diagnosis for detecting prognostically important genomic abnormalities in leukemias/lymphomas and solid tumors involving: <ul style="list-style-type: none"> • Loss/gain of DNA • Loss of heterozygosity (LOH)
0040227	<i>IGHV</i> Mutation Analysis by Sequencing	Determines risk group in newly diagnosed CLL.
2012844	CD200 by Immunohistochemistry	Primarily aids in the distinction between CLL/SLL and mantle-cell lymphoma where CD200 is usually positive in CLL/SLL and negative in mantle cell lymphoma; CD200 is also positive in other B-cell lymphoproliferative disorders.
0049250	p53 with Interpretation by Immunohistochemistry	Determine risk group for newly diagnosed CLL.
2008003	Leukemia/Lymphoma Phenotyping by Flow Cytometry	Aids in evaluation of hematopoietic neoplasms (i.e., leukemia, lymphoma).

